Legal Representation
Attorney
Elizabeth A. Walker
USPTO Deadlines
Next Deadline
61 days remaining
NOA E-Mailed - SOU Required
Due Date
October 01, 2025
Extension Available
Until April 01, 2026
Application History
19 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Apr 1, 2025 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | Loading... |
| Feb 4, 2025 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Feb 4, 2025 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Jan 29, 2025 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Jan 15, 2025 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Jan 15, 2025 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
| Jan 15, 2025 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Jan 15, 2025 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Nov 29, 2024 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Nov 27, 2024 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Nov 27, 2024 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Aug 28, 2024 | XELR | I | APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED | Loading... |
| Aug 28, 2024 | XELG | O | APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED | Loading... |
| May 31, 2024 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| May 31, 2024 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| May 31, 2024 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
| May 24, 2024 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Oct 13, 2023 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Oct 7, 2023 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 005
House mark for the following, namely, Pharmaceutical preparations for the treatment of cardiovascular diseases, disorders, and defects; Pharmaceutical preparations for the treatment of Friedreich's Ataxia; Pharmaceutical preparations for the treatment of arrhythmogenic cardiomyopathy; Pharmaceutical preparations for the treatment of hypertrophic cardiomyopathy; Pharmaceutical preparations for the treatment of central nervous system diseases, disorders, and defects; Pharmaceutical preparations for the treatment of Alzheimer's disease; Pharmaceutical preparations for the treatment of Batten disease; Pharmaceutical preparations for the treatment of genetic diseases, disorders, and defects; Pharmaceutical preparations for the treatment of monogenic diseases, disorders, and defects; Biologic gene therapy preparations for the treatment of diseases, disorders, and defects; Therapeutic agents for delivery of genetically engineered viruses to patients for targeting underlying causes of diseases, disorders, and defects for treatment therefor; Therapeutic agents for delivery of genetically engineered viruses to patients for treatment of diseases, disorders, and defects; Pharmaceutical preparations for the detection or diagnosis of cardiovascular diseases, disorders, and defects; Pharmaceutical preparations for the detection or diagnosis of Friedreich's Ataxia; Pharmaceutical preparations for the detection or diagnosis of arrhythmogenic cardiomyopathy; Pharmaceutical preparations for the detection or diagnosis of hypertrophic cardiomyopathy; Pharmaceutical preparations for the detection or diagnosis of central nervous system diseases, disorders, and defects; Pharmaceutical preparations for the detection or diagnosis of Alzheimer's disease; Pharmaceutical preparations for the detection or diagnosis of Batten disease; Pharmaceutical preparations for the detection or diagnosis of genetic diseases, disorders, and defects; Pharmaceutical preparations for the detection or diagnosis of monogenic diseases, disorders, and defects; Biologic gene therapy preparations for the detection or diagnosis of diseases, disorders, and defects; Therapeutic agents for delivery of genetically engineered viruses to patients for detection or diagnosis of underlying causes of diseases, disorders, and defects; Therapeutic agents for delivery of genetically engineered viruses to patients for detection or diagnosis of diseases, disorders, and defects
Classification
International Classes
005